Webinar: Precision Medicine and Alzheimer’s Disease: Overcoming Biomarker Testing Barriers for Alzheimer’s Disease Patients
Tuesday, October 03, 2023 | 12pm EDT / 11am CDT / 9am PDT / 5pm BST (UK) / 6pm CEST (EU-Central)
admin.veranex : Mar 24, 2025 10:22:50 PM
Jordan Hinahara and Thomas Goss, members of our Commercial Strategy and Market Access team, contributed to the budget impact model. The objective was to evaluate the economic impact of dasiglucagon compared with available glucagon treatments for SHE management, considering direct cost of treatment and health care resource utilization.
Tuesday, October 03, 2023 | 12pm EDT / 11am CDT / 9am PDT / 5pm BST (UK) / 6pm CEST (EU-Central)
1 min read
Recently two Veranex employees volunteered their time and expertise to IFPx — a company working on a device to monitor and proactively treat...
1 min read
As the world is beginning to understand, SARS-CoV-2 poses several unique challenges. Asymptomatic and infected individuals are highly contagious...